Insider Buying: Oncocyte (NASDAQ:IMDX) Major Shareholder Buys $157,877.20 in Stock

Oncocyte Corp (NASDAQ:IMDX) major shareholder Broadwood Partners, L.P. purchased 40,690 shares of the stock in a transaction that occurred on Monday, April 20th. The stock was purchased at an average price of $3.88 per share, with a total value of $157,877.20. Following the acquisition, the insider directly owned 12,114,700 shares of the company’s stock, valued at $47,005,036. This trade represents a 0.34% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

Broadwood Partners, L.P. also recently made the following trade(s):

• On Friday, April 17th, Broadwood Partners, L.P. purchased 40,114 shares of Oncocyte stock. The stock was purchased at an average price of $3.57 per share, with a total value of $143,206.98.
• On Thursday, April 16th, Broadwood Partners, L.P. purchased 102,057 shares of Oncocyte stock. The stock was purchased at an average price of $3.45 per share, with a total value of $352,096.65.
• On Tuesday, February 10th, Broadwood Partners, L.P. purchased 521,739 shares of Oncocyte stock. The stock was purchased at an average price of $5.75 per share, with a total value of $2,999,999.25.

Oncocyte Stock Up 4.7%

Shares of NASDAQ:IMDX opened at $3.75 on Thursday. The company has a market capitalization of $120.64 million, a P/E ratio of -2.31 and a beta of 1.52. Oncocyte Corp has a 52 week low of $2.33 and a 52 week high of $8.51. The business has a 50 day simple moving average of $4.45.

Oncocyte (NASDAQ:IMDX) last issued its quarterly earnings data on Thursday, March 26th. The company reported ($0.27) EPS for the quarter. The company had revenue of $1.14 million for the quarter.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on IMDX shares. Wall Street Zen downgraded shares of Oncocyte from a “hold” rating to a “sell” rating in a research note on Saturday, March 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Oncocyte in a research note on Friday, March 27th. Finally, Lake Street Capital boosted their price objective on shares of Oncocyte from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Tuesday, February 17th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $12.00.

About Oncocyte

Oncocyte (NASDAQ:IMDX) is a molecular diagnostics company that develops and commercializes tests intended to improve cancer detection, risk stratification and treatment decision-making. The company focuses on creating assays that provide clinically actionable information to physicians managing patients with suspected or confirmed malignancies, with particular emphasis on tools that can help evaluate lung nodules and other oncology-related diagnostic challenges.

Oncocyte’s product and development efforts center on blood- and tissue-based molecular assays that analyze biomarkers and genomic signals to inform clinical workflows.